|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.115 AUD | -4.17% |
|
0.00% | 0.00% |
| Mar. 26 | Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise | MT |
| Mar. 20 | Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12% | MT |
Arovella Therapeutics Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported sales was AUD 0.29581 million compared to AUD 0.257347 million a year ago. Net loss was AUD 8.62 million compared to AUD 5.05 million a year ago.
Basic loss per share from continuing operations was AUD 0.0157 compared to AUD 0.0152 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 81.67M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
AROVELLA THERAPEUTICS LIMITED 
